Cerebrolysin and TBI: The Recovery Evidence

Cerebrolysin

8,749 TBI patients studied

A 2023 systematic review pooling 10 clinical studies found cerebrolysin treatment was associated with statistically significant improvements in Glasgow Coma Scale and Glasgow Outcome Scale scores.

Jarosz et al., Brain Sciences, 2023

Jarosz et al., Brain Sciences, 2023

View as image

Traumatic brain injury causes an estimated 69 million hospitalizations globally each year, and no FDA-approved drug exists specifically for TBI recovery. Cerebrolysin, a porcine brain-derived peptide preparation containing neurotrophic factor fragments, has been studied in TBI patients more extensively than any other peptide-based intervention. A 2023 meta-analysis pooling 10 clinical studies and 8,749 patients found statistically significant improvements in neurological and functional outcomes.^[1] For broader context on cerebrolysin's pharmacology and clinical uses, see our overview of cerebrolysin for vascular dementia.

This article examines the full body of TBI-specific evidence: the CAPTAIN randomized controlled trials, the retrospective cohort data, the dose-response relationship established in preclinical models, and the gaps that remain before this evidence base can support definitive clinical conclusions.

What Cerebrolysin Is and How It Relates to TBI Pathophysiology

Cerebrolysin is a standardized mixture of approximately 25% low-molecular-weight peptides and 75% free amino acids produced through enzymatic degradation of porcine brain tissue. The peptide fraction contains fragments that mimic the activity of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).^[2]

TBI triggers a cascade of secondary injury mechanisms: excitotoxicity, oxidative stress, neuroinflammation, blood-brain barrier disruption, and apoptosis. These secondary processes continue for days to weeks after the initial mechanical injury and are responsible for much of the eventual disability. A 2012 study demonstrated that cerebrolysin reduced oxidative stress-induced apoptosis in lymphocytes, providing evidence that its protective effects extend to cellular-level damage reduction.^[3] Cerebrolysin's multi-target pharmacology addresses several of these secondary injury pathways simultaneously, which is the theoretical rationale for its use in a condition where single-target drugs have repeatedly failed clinical trials.

A 2023 comprehensive review documented that cerebrolysin activates neurotrophic signaling cascades (PI3K/Akt and MAPK/ERK pathways), reduces oxidative damage markers, suppresses microglial activation, and promotes synaptic plasticity and axonal sprouting in both in vitro and in vivo models.^[4] This multi-modal mechanism distinguishes it from single-molecule approaches that have historically failed to translate from animal models to human TBI outcomes. For a deeper look at the molecular mechanisms involved, our article on how cerebrolysin works covers the signaling pathways in detail.

The CAPTAIN Trial Program: The Strongest Evidence

The CAPTAIN (Cerebrolysin And Recovery After Acute Brain Injury: Analysis of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial) program represents the highest-quality evidence for cerebrolysin in TBI.

CAPTAIN I

This multicenter, randomized, double-blind, placebo-controlled trial enrolled patients with moderate-to-severe TBI (Glasgow Coma Score 6-12) across centers in the Asia-Pacific region. Patients received either cerebrolysin (50 mL/day for 10 days, followed by two additional 10-day cycles at 10 mL/day) or placebo in addition to standard care. The primary endpoint was a multidimensional composite of functional and neuropsychological outcomes. Cerebrolysin-treated patients showed improvements in GOSE scores, with a safety profile comparable to placebo.^[5]

CAPTAIN II

The second trial expanded the program to additional centers with the same double-blind, placebo-controlled design. Patients with GCS 7-12 received the same dosing protocol. CAPTAIN II confirmed the safety and efficacy findings and demonstrated particularly notable effects in the moderate TBI subgroup. The trial provided the individual patient data that made the prospective meta-analysis possible.^[6]

CAPTAIN Prospective Meta-Analysis

A total of 185 patients across both CAPTAIN trials underwent prospective meta-analysis (mean admission GCS = 10.3, mean age = 45.3). The primary endpoint, a multidimensional ensemble of functional and neuropsychological outcome scales, showed a "small-to-medium" effect size (Cohen's d) in favor of cerebrolysin. This effect was statistically significant at both Day 30 and Day 90.^[7]

The statistical significance at two separate time points is notable because it suggests the benefit is not transient. The Day 30 finding indicates an acute neuroprotective effect, while the Day 90 finding suggests sustained neurorestorative benefit extending well beyond the treatment period itself.

CAPTAIN II Retrospective Analysis: Psychiatric Outcomes

A 2022 retrospective analysis of CAPTAIN II data examined cerebrolysin's effects on anxiety, depression, and cognition specifically. In the moderate TBI subgroup, cerebrolysin-treated patients showed reduced Hospital Anxiety and Depression Scale (HADS) anxiety and depression subscale scores at Day 90 compared to placebo. Cognitive assessment also showed improvements in this subgroup. The severe TBI subgroup did not show the same psychiatric benefits, suggesting the effect may be ceiling-limited in the most severely injured patients.^[8]

The Mild TBI Evidence

Only one published placebo-controlled RCT has examined cerebrolysin in mild traumatic brain injury. Chen and colleagues (2013) enrolled 32 patients with mild TBI (GCS 13-15, with documented intracranial contusion hemorrhage) within 24 hours of injury in Taiwan. Patients received either cerebrolysin (30 mL/day intravenously for 5 days) or saline placebo.^[9]

At 3 months, the cerebrolysin group showed significantly greater improvement on the Cognitive Abilities Screening Instrument (CASI): a mean change of 21.0 points versus 7.6 points for placebo (p = 0.046). Drawing function improved significantly at both 4 weeks (p = 0.007) and 12 weeks (p = 0.047). Long-term memory showed significant improvement at 12 weeks (p = 0.026).

The study's limitations are substantial. Thirty-two patients is a pilot-scale sample. It was a single-center trial. The 5-day treatment window is brief and was administered only to hospitalized patients with visible contusions, not the typical outpatient concussion population. No follow-up beyond 3 months was reported. For more detail on this mild TBI data, see our concussion-focused review.

The Large Retrospective Cohort

The largest observational dataset comes from a 2015 retrospective multicenter cohort study examining 7,784 TBI patients treated at centers where cerebrolysin was part of standard care. Muresanu and colleagues analyzed outcomes stratified by injury severity (mild, moderate, severe) and found severity-dependent effects.^[10]

Mild TBI patients receiving cerebrolysin showed improvements at Day 10. Moderate and severe TBI patients showed improvements at Days 10 and 30. All cerebrolysin-treated patients with cerebral contusion and diffuse axonal injury showed favorable GCS at Day 21. The severity-dependent timing pattern is consistent with what would be expected from a neuroprotective agent: milder injuries recover faster, while more severe injuries take longer to show measurable benefit.

A separate cohort study focused specifically on severe TBI patients with persistent disability found that cerebrolysin treatment was associated with improved functional recovery, decreased mortality, and increased rates of favorable outcomes compared to controls.^[11]

The retrospective design of both studies limits causal conclusions. Physicians who prescribe cerebrolysin may differ systematically from those who do not, and patient selection effects cannot be excluded. These studies should be viewed as supportive of the RCT findings, not as independent proof.

Dose-Response and Treatment Timing

A 2018 prospective, randomized, blinded, placebo-controlled study in a rat TBI model established that cerebrolysin's effects are both dose-dependent and time-dependent. Zhang and colleagues tested doses ranging from 0.8 to 7.5 mL/kg administered starting 4 hours after injury and then daily for 10 days. The 2.5 mL/kg dose produced the strongest improvements in spatial memory (Morris water maze) and motor function (mNSS), with higher and lower doses showing lesser effects, suggesting an inverted-U dose-response curve.^[12]

In clinical practice, dosing protocols have varied considerably across studies. The mild TBI trial used 30 mL/day for 5 days. The CAPTAIN trials used 50 mL/day for 10 days followed by two additional 10-day cycles at 10 mL/day. The optimal dose for human TBI has not been established through formal dose-finding studies, and the animal data suggesting a bell-shaped response curve raises the possibility that some clinical trials may have used suboptimal doses.

How This Evidence Compares

No other peptide preparation has this volume of TBI clinical trial data. The CAPTAIN program's prospective meta-analysis design is relatively rigorous, and the consistent direction of effect across controlled and observational studies provides a coherent evidence picture.

That said, the total RCT evidence (approximately 217 patients across the mild TBI trial and CAPTAIN program) is small by modern TBI trial standards, where phase III trials typically enroll 800-1,500 patients. The observational data is large (7,784 patients) but methodologically weaker. A 2024 comparative study confirmed that cerebrolysin's composition and biological activity are distinct from other commercially available peptide preparations, making cross-product extrapolation unreliable.^[13]

The drug's effect on mortality is consistently neutral across studies. The 2023 meta-analysis found no impact on mortality rates or hospital stay duration.^[1] The benefits appear concentrated in functional and cognitive outcomes rather than survival, which is an important distinction. This pattern, where a neuroprotective agent improves recovery quality without affecting acute mortality, is consistent with what neurotrophic factors do biologically: they support neuronal repair and plasticity rather than preventing cell death in the acute injury window.

Cerebrolysin has no FDA approval, and the evidence base may not meet the standards required for US regulatory approval. Most trials were conducted in Europe, Asia, and Latin America, and differences in standard TBI care between these regions and US practice may affect generalizability. The absence of large, US-based phase III trials is the single largest barrier to regulatory progress and to adoption by US clinicians who treat TBI patients. For context on cerebrolysin's stroke evidence, which has been more mixed, see our article on cerebrolysin in stroke recovery. For Alzheimer's disease evidence, which represents a separate body of work with this same preparation, see our Alzheimer's clinical trial review.

The Cost-Effectiveness Question

A cost-effectiveness analysis based on the CAPTAIN trial data evaluated cerebrolysin's economic viability as an add-on TBI treatment. The analysis found a high probability that cerebrolysin is cost-effective in moderate TBI patients when considering the long-term costs of disability, rehabilitation, and lost productivity that improved functional outcomes could avert. However, these economic models depend on assumptions about the durability of treatment effects and the per-patient cost of the IV infusion protocol, both of which carry uncertainty. The economic case is weaker for mild TBI (where patients typically recover spontaneously) and for the most severe injuries (where the treatment effect appears smaller).

Open Questions and Evidence Gaps

Several critical questions remain unanswered. The optimal timing of treatment initiation after TBI has not been established; animal data suggests earlier is better, but the clinical trials started treatment at varying intervals from 24 hours to several days post-injury. Whether delayed treatment in the rehabilitation phase provides additional benefit is addressed by some observational data but no RCTs.

The patient subpopulations most likely to benefit are not well characterized. The CAPTAIN II retrospective analysis suggests moderate TBI patients may benefit more from psychiatric symptom reduction than severe TBI patients, but this finding requires prospective confirmation. Whether specific injury patterns (contusion versus diffuse axonal injury versus subdural hematoma) respond differently is unknown.

The IV-only route of administration remains a practical barrier, particularly for mild TBI patients who are typically managed as outpatients. No oral formulation exists, and the peptide mixture would likely be degraded by gastrointestinal enzymes if taken orally.

The Bottom Line

Cerebrolysin has more clinical trial data in traumatic brain injury than any other peptide preparation. The CAPTAIN trial series provides controlled evidence of a small-to-medium functional benefit in moderate-severe TBI at 30 and 90 days, supported by a large retrospective cohort of 7,784 patients. A small RCT supports cognitive recovery benefits in mild TBI. The evidence consistently shows functional and cognitive improvement without mortality reduction. The primary gaps are the modest total RCT sample sizes, absence of large phase III trials, lack of FDA approval, and unresolved questions about optimal dosing, timing, and patient selection.

Frequently Asked Questions

Does cerebrolysin work for traumatic brain injury?

Clinical evidence suggests cerebrolysin improves functional and cognitive outcomes after TBI, though it does not reduce mortality. A prospective meta-analysis of the CAPTAIN trials found statistically significant improvements at 30 and 90 days, and a 2023 systematic review of 8,749 patients confirmed significant improvements in GCS and GOS scores. The evidence is strongest for moderate-severe TBI.

What is the cerebrolysin dose for TBI?

Clinical trials have used 30-50 mL/day given intravenously. The CAPTAIN trials used 50 mL/day for 10 days followed by two additional 10-day cycles at 10 mL/day. The mild TBI trial used 30 mL/day for 5 days. Animal studies suggest the dose-response relationship follows an inverted-U curve, meaning higher doses do not necessarily produce better outcomes.

Is cerebrolysin approved for brain injury treatment?

Cerebrolysin is approved for TBI treatment in over 45 countries across Europe, Asia, and Latin America, but it is not FDA-approved in the United States for any indication. Regulatory standards and evidentiary requirements vary by country. Most clinical trials were conducted outside the US.

How long does cerebrolysin take to work after TBI?

In the CAPTAIN trial series, statistically significant functional improvements were measurable at Day 30 and sustained through Day 90. In the mild TBI trial, cognitive improvements became significant at 3 months post-injury. A retrospective cohort showed mild TBI improvements at Day 10, while moderate and severe cases showed improvements at Days 10 and 30.

What are the side effects of cerebrolysin in TBI patients?

Across the CAPTAIN trials and other TBI studies, cerebrolysin had a safety profile comparable to placebo. Commonly reported adverse events include dizziness, headache, and injection site reactions. No serious safety signals have been identified. The drug is derived from porcine brain tissue, which carries a theoretical risk of allergic reaction in sensitized individuals.

Can cerebrolysin help with concussion symptoms?

One placebo-controlled trial of 32 mild TBI patients found cerebrolysin improved cognitive function, long-term memory, and drawing ability at 3 months versus placebo. The evidence for concussion specifically is limited to this single small study. The larger CAPTAIN trial data applies to moderate-severe TBI, not typical outpatient concussions. The IV-only route of administration also limits practical use for most concussion patients.